NASDAQ:REPL Replimune Group (REPL) Stock Forecast, Price & News $17.11 +0.61 (+3.70%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$15.67▼$17.1450-Day Range$15.96▼$21.3252-Week Range$15.51▼$29.52Volume1.26 million shsAverage Volume625,998 shsMarket Capitalization$1.01 billionP/E RatioN/ADividend YieldN/APrice Target$51.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Replimune Group MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside201.6% Upside$51.60 Price TargetShort InterestBearish19.43% of Float Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment0.93Based on 2 Articles This WeekInsider TradingSelling Shares$939,000 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.37) to ($3.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector373rd out of 972 stocksBiological Products, Except Diagnostic Industry59th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingReplimune Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $51.60, Replimune Group has a forecasted upside of 201.6% from its current price of $17.11.Amount of Analyst CoverageReplimune Group has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted19.43% of the float of Replimune Group has been sold short.Short Interest Ratio / Days to CoverReplimune Group has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.Change versus previous monthShort interest in Replimune Group has recently increased by 3.43%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreReplimune Group has received a 69.41% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for Replimune Group is -1.28. Previous Next 3.3 News and Social Media Coverage News SentimentReplimune Group has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Replimune Group this week, compared to 2 articles on an average week.Search Interest5 people have searched for REPL on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows2 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $939,000.00 in company stock.Percentage Held by Insiders20.60% of the stock of Replimune Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Replimune Group are expected to decrease in the coming year, from ($3.37) to ($3.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -5.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -5.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Replimune Group (NASDAQ:REPL) StockReplimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Read More REPL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REPL Stock News HeadlinesOctober 1, 2023 | americanbankingnews.comReplimune Group (NASDAQ:REPL) Stock Price Down 3.2%September 14, 2023 | finance.yahoo.comInsider Sell: Pamela Esposito Sells 5,658 Shares of Replimune Group IncOctober 1, 2023 | Legacy Research (Ad)Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”September 10, 2023 | fool.comReplimune Group (NASDAQ: REPL)August 14, 2023 | msn.comReplimune: Q4 2023 Data Readouts Of RP1 Makes This A Must WatchAugust 9, 2023 | msn.comUnusual Put Option Trade in Replimune Group (REPL) Worth $810.00KAugust 8, 2023 | markets.businessinsider.comArvinas Holding Company (ARVN) Receives a Buy from BarclaysAugust 3, 2023 | finance.yahoo.comReplimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate UpdateOctober 1, 2023 | Legacy Research (Ad)Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”August 1, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Replimune GroupJuly 31, 2023 | finance.yahoo.comReplimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell CarcinomaJuly 20, 2023 | finance.yahoo.comReplimune Announces Sander Slootweg will Depart from its Board of DirectorsJuly 13, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Replimune Group (REPL)July 9, 2023 | msn.comReplimune: The Rise Of Oncolytic Virus Therapies In Cancer TreatmentJune 28, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Aldeyra Therapeutics (ALDX), Replimune Group (REPL)June 9, 2023 | msn.comHC Wainwright & Co. Reiterates Replimune Group (REPL) Buy RecommendationJune 6, 2023 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Replimune Group (REPL)June 6, 2023 | finance.yahoo.comReplimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) MeetingJune 6, 2023 | msn.comHC Wainwright & Co. Maintains Replimune Group (REPL) Buy RecommendationJune 5, 2023 | benzinga.comDirector at Replimune Group Acquires Company Stock Options Worth 50,400 SharesJune 5, 2023 | markets.businessinsider.comEF Hutton Remains a Buy on Replimune Group (REPL)June 5, 2023 | finance.yahoo.comReplimune Appoints Veleka R. Peeples-Dyer to its Board of DirectorsJune 3, 2023 | tmcnet.comReplimune Presents RP1 Data from the IGNYTE anti-…June 3, 2023 | finance.yahoo.comReplimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingJune 1, 2023 | finance.yahoo.comReplimune to Present at the Jefferies Global Healthcare ConferenceMay 29, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Replimune Group (REPL)May 26, 2023 | msn.comEF Hutton Reiterates Replimune Group (REPL) Buy RecommendationSee More Headlines Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Email Address REPL Company Calendar Last Earnings8/03/2023Today10/01/2023Next Earnings (Estimated)11/02/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:REPL CUSIPN/A CIK1737953 Webwww.replimune.com Phone(781) 222-9600FaxN/AEmployees284Year Founded2015Price Target and Rating Average Stock Price Forecast$51.60 High Stock Price Forecast$70.00 Low Stock Price Forecast$34.00 Forecasted Upside/Downside+201.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-174,280,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.45% Return on Assets-30.71% Debt Debt-to-Equity Ratio0.10 Current Ratio17.06 Quick Ratio17.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.80 per share Price / Book1.75Miscellaneous Outstanding Shares59,000,000Free Float46,843,000Market Cap$1.01 billion OptionableNot Optionable Beta1.63 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Philip Astley-Sparke F.S.A. (Age 52)FSA, CEO, Interim CFO & Director Comp: $1.07MDr. Sushil Patel Ph.D. (Age 52)Chief Strategy Officer Comp: $665.05kDr. Robert Coffin Ph.D. (Age 58)Founder, Pres, Chief R&D Officer and Director Dr. Colin A. Love Ph.D. (Age 65)Chief Operating Officer Mr. Andrew Schwendenman (Age 47)Chief Accounting Officer & Treasurer Dr. Pamela Esposito Ph.D. (Age 49)Chief Bus. Officer Ms. Tanya N. Lewis M.S. (Age 52)Chief Devel. Operations Officer Mr. Christopher Sarchi (Age 55)Chief Commercial Officer Dr. Konstantinos Xynos M.B.A. (Age 57)M.D., Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsProKidneyNASDAQ:PROKInhibrxNASDAQ:INBXRelay TherapeuticsNASDAQ:RLAYImmaticsNASDAQ:IMTXPrime MedicineNYSE:PRMEView All CompetitorsInsiders & InstitutionsPamela EspositoSold 5,358 sharesTotal: $107,213.58 ($20.01/share)Pamela EspositoSold 18,600 sharesTotal: $372,186.00 ($20.01/share)California State Teachers Retirement SystemSold 2,873 shares on 8/21/2023Ownership: 0.078%Alliancebernstein L.P.Bought 9,601 shares on 8/15/2023Ownership: 0.079%Wells Fargo & Company MNSold 4,384 shares on 8/15/2023Ownership: 0.068%View All Insider TransactionsView All Institutional Transactions REPL Stock - Frequently Asked Questions Should I buy or sell Replimune Group stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" REPL shares. View REPL analyst ratings or view top-rated stocks. What is Replimune Group's stock price forecast for 2023? 5 analysts have issued 1 year target prices for Replimune Group's stock. Their REPL share price forecasts range from $34.00 to $70.00. On average, they anticipate the company's stock price to reach $51.60 in the next twelve months. This suggests a possible upside of 201.6% from the stock's current price. View analysts price targets for REPL or view top-rated stocks among Wall Street analysts. How have REPL shares performed in 2023? Replimune Group's stock was trading at $27.20 on January 1st, 2023. Since then, REPL shares have decreased by 37.1% and is now trading at $17.11. View the best growth stocks for 2023 here. When is Replimune Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our REPL earnings forecast. How were Replimune Group's earnings last quarter? Replimune Group, Inc. (NASDAQ:REPL) released its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.05. During the same quarter last year, the company earned ($0.78) EPS. What ETFs hold Replimune Group's stock? ETFs with the largest weight of Replimune Group (NASDAQ:REPL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Horizon Kinetics Medical ETF (MEDX), First Trust Innovation Leaders ETF (ILDR).ALPS Medical Breakthroughs ETF (SBIO), What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC). When did Replimune Group IPO? (REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. What is Replimune Group's stock symbol? Replimune Group trades on the NASDAQ under the ticker symbol "REPL." How do I buy shares of Replimune Group? Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Replimune Group's stock price today? One share of REPL stock can currently be purchased for approximately $17.11. How much money does Replimune Group make? Replimune Group (NASDAQ:REPL) has a market capitalization of $1.01 billion. The company earns $-174,280,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis. How many employees does Replimune Group have? The company employs 284 workers across the globe. How can I contact Replimune Group? Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for the company is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at ir@replimune.com. This page (NASDAQ:REPL) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.